Phase Ib dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with metastatic squamous (sq) and non-squamous (non-sq) non-small cell lung cancer (NSCLC)

Y. Yu; D. Huang; B. Gao; J. Zhao; Y. Hu; W. Zhuang; S. Kao; W. Xu; Y. Yao; T-Y. Yang; Y. Lee; J-S. Kim; H-S. Shiah; R. Wang; H. Zheng; W. Tan; R. Gao; H.R. Kim; S. Lu

doi:10.1016/j.annonc.2022.07.1143

YUHSpace

BROWSE

0 213

Cited 0 times in

Phase Ib dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with metastatic squamous (sq) and non-squamous (non-sq) non-small cell lung cancer (NSCLC)

Authors: Y. Yu ; D. Huang ; B. Gao ; J. Zhao ; Y. Hu ; W. Zhuang ; S. Kao ; W. Xu ; Y. Yao ; T-Y. Yang ; Y. Lee ; J-S. Kim ; H-S. Shiah ; R. Wang ; H. Zheng ; W. Tan ; R. Gao ; H.R. Kim ; S. Lu